<?xml version="1.0"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/"><rdf:Description rdf:about="https://dirros.openscience.si/IzpisGradiva.php?id=14959"><dc:title>SERPING1 variants and C1-INH biological function : a close relationship with C1-INH-HAE</dc:title><dc:creator>Drouet,	Christian	(Avtor)
	</dc:creator><dc:creator>López Lera,	Alberto	(Avtor)
	</dc:creator><dc:creator>Ghannam,	Arije	(Avtor)
	</dc:creator><dc:creator>López-Trascasa,	Margarita	(Avtor)
	</dc:creator><dc:creator>Cichon,	Sven	(Avtor)
	</dc:creator><dc:creator>Ponard,	Denise	(Avtor)
	</dc:creator><dc:creator>Parsopoulou,	Faidra	(Avtor)
	</dc:creator><dc:creator>Grombirikova,	Hana	(Avtor)
	</dc:creator><dc:creator>Freiberger,	Tomas	(Avtor)
	</dc:creator><dc:creator>Rijavec,	Matija	(Avtor)
	</dc:creator><dc:creator>Lopes Veronez,	Camila	(Avtor)
	</dc:creator><dc:creator>Pesquero,	João Bosco	(Avtor)
	</dc:creator><dc:creator>Germenis,	Anastasios E.	(Avtor)
	</dc:creator><dc:subject>Hereditary angioedemas -- genetics -- diagnosis</dc:subject><dc:subject>genetic variation</dc:subject><dc:subject>serpins</dc:subject><dc:subject>SERPING1 gene</dc:subject><dc:subject>C1-INH</dc:subject><dc:subject>C1-INH-HAE</dc:subject><dc:subject>C1 inhibitor</dc:subject><dc:subject>serpinopathy</dc:subject><dc:description>Hereditary angioedema with C1 Inhibitor deficiency (C1-INH-HAE) is caused by a constellation of variants of the SERPING1 gene (n = 809; 1,494 pedigrees), accounting for 86.8% of HAE families, showing a pronounced mutagenic liability of SERPING1 and pertaining to 5.6% de novo variants. C1-INH is the major control serpin of the kallikrein–kinin system (KKS). In addition, C1-INH controls complement C1 and plasminogen activation, both systems contributing to inflammation. Recognizing the failed control of C1s protease or KKS provides the diagnosis of C1-INH-HAE. SERPING1 variants usually behave in an autosomal-dominant character with an incomplete penetrance and a low prevalence. A great majority of variants (809/893; 90.5%) that were introduced into online database have been considered as pathogenic/likely pathogenic. Haploinsufficiency is a common feature in C1-INH-HAE where a dominant-negative variant product impacts the wild-type allele and renders it inactive. Small (36.2%) and large (8.3%) deletions/duplications are common, with exon 4 as the most affected one. Point substitutions with missense variants (32.2%) are of interest for the serpin structure–function relationship. Canonical splice sites can be affected by variants within introns and exons also (14.3%). For noncanonical sequences, exon skipping has been confirmed by splicing analyses of patients' blood-derived RNAs (n = 25). Exonic variants (n = 6) can affect exon splicing. Rare deep-intron variants (n = 6), putatively acting as pseudo-exon activating mutations, have been characterized as pathogenic. Some variants have been characterized as benign/likely benign/of uncertain significance (n = 74). This category includes some homozygous (n = 10) or compound heterozygous variants (n = 11). They are presenting with minor allele frequency (MAF) below 0.00002 (i.e., lower than C1-INH-HAE frequency), and may be quantitatively unable to cause haploinsufficiency. Rare benign variants could contribute as disease modifiers. Gonadal mosaicism in C1-INH-HAE is rare and must be distinguished from a de novo variant. Situations with paternal or maternal disomy have been recorded (n = 3). Genotypes must be interpreted with biological investigation fitting with C1-INH expression and typing. Any SERPING1 variant reminiscent of the dysfunctional phenotype of serpin with multimerization or latency should be identified as serpinopathy.</dc:description><dc:publisher>Frontiers</dc:publisher><dc:date>2022</dc:date><dc:date>2022-04-06 11:49:19</dc:date><dc:type>Neznano</dc:type><dc:identifier>14959</dc:identifier><dc:language>sl</dc:language><dc:rights>© 2022 Drouet, López-Lera, Ghannam, López-Trascasa, Cichon, Ponard, Parsopoulou, Grombirikova, Freiberger, Rijavec, Veronez, Pesquero and Germenis</dc:rights></rdf:Description></rdf:RDF>
